Senores Pharmaceuticals Ltd

Senores Pharmaceuticals has reached a new 52-week high of Rs.832, marking a notable milestone in its stock performance amid a broadly positive market environment.

Senores Pharmaceuticals, a key player in the Pharmaceuticals & Biotechnology sector, has reached an all-time high, marking a significant milestone in its market journey. The stock's recent performance reflects robust momentum, supported by consistent price strength and favourable trading patterns.

Senores Pharmaceuticals achieved a new 52-week high of Rs. 831.65 on November 7, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has outperformed its sector and demonstrated resilience with consecutive gains, trading above key moving averages and showing significant recovery from its previous low.

Senores Pharmaceuticals has achieved an all-time high of Rs. 830.3, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has shown consistent upward momentum, gaining 8.28% over two days and outperforming the Sensex significantly year-to-date, highlighting the company's robust market strength and growth trajectory.

Senores Pharmaceuticals has reported record financial results for the quarter ending September 2025, with net sales of Rs 161.76 crore and a profit after tax of Rs 32.38 crore. Despite facing high interest expenses, the company has significantly outperformed the Sensex, showcasing its strong market position.

Senores Pharmaceuticals Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹3,724 crores, delivered an impressive performance in Q2 FY26, reporting consolidated net profit of ₹32.38 crores—a remarkable 152.18% surge year-on-year and 64.12% sequential growth. The stock responded enthusiastically, surging 5.09% to ₹805.80 on November 6, 2025, trading near its 52-week high of ₹829.55 and reflecting strong investor confidence in the company's growth trajectory.

Senores Pharmaceuticals achieved a new 52-week high of Rs. 817.7 on November 6, 2025, reflecting strong performance in the pharmaceuticals sector. The stock outperformed its sector and is trading above key moving averages, indicating a positive trend amidst a generally bullish market sentiment.

Senores Pharmaceuticals achieved an all-time high of Rs. 809.45 on November 6, 2025, showcasing its strong performance in the pharmaceuticals sector. The stock's notable intraday rise and consistent trading above key moving averages indicate robust investor confidence and resilience, with significant gains over the past month and year-to-date.

Senores Pharmaceuticals achieved a new 52-week high of Rs. 793.95 on October 29, 2025, reflecting its strong performance over the past year. Despite this milestone, the stock has underperformed compared to its sector. The broader market, represented by the Sensex, is also showing positive trends.

Senores Pharmaceuticals has achieved an all-time high stock price, highlighting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown resilience with significant growth over the past week and month, outperforming the Sensex, and demonstrating robust year-to-date performance.

Senores Pharmaceuticals has achieved a new 52-week high of Rs. 788.65, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The stock has consistently gained over the past three days and is trading above multiple moving averages, indicating a robust upward trend amid a resilient broader market.

Senores Pharmaceuticals has achieved an all-time high of Rs. 788.65, reflecting strong investor confidence and consistent upward momentum. The company has outperformed its sector and demonstrated resilience with a significant year-to-date increase, marking a notable milestone in the small-cap pharmaceuticals and biotechnology industry.

Senores Pharmaceuticals reached an all-time high of Rs. 782.7 on October 27, 2025, reflecting its strong position in the Pharmaceuticals & Biotechnology sector. The stock has shown resilience, outperforming the Sensex over various timeframes and trading above key moving averages, indicating robust performance and potential for future growth.

Senores Pharmaceuticals achieved a new 52-week high of Rs. 782.7 on October 27, 2025, demonstrating strong performance in the Pharmaceuticals & Biotechnology sector. The stock has shown resilience with consecutive gains and is trading above key moving averages, reflecting a positive shift in market sentiment amid broader bullish trends.